Page last updated: 2024-09-05
tesaglitazar and gw 3965
tesaglitazar has been researched along with gw 3965 in 1 studies
Compound Research Comparison
Studies (tesaglitazar) | Trials (tesaglitazar) | Recent Studies (post-2010) (tesaglitazar) | Studies (gw 3965) | Trials (gw 3965) | Recent Studies (post-2010) (gw 3965) |
---|---|---|---|---|---|
74 | 13 | 25 | 235 | 0 | 164 |
Protein Interaction Comparison
Protein | Taxonomy | tesaglitazar (IC50) | gw 3965 (IC50) |
---|---|---|---|
Alpha-glucosidase MAL32 | Saccharomyces cerevisiae S288C | 4.8 | |
Oxysterols receptor LXR-beta | Homo sapiens (human) | 0.47 | |
Oxysterols receptor LXR-alpha | Homo sapiens (human) | 0.5691 |
Research
Studies (1)
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 1 (100.00) | 2.80 |
Authors
Authors | Studies |
---|---|
Ferrara, SJ; Scanlan, TS | 1 |
Other Studies
1 other study(ies) available for tesaglitazar and gw 3965
Article | Year |
---|---|
A CNS-Targeting Prodrug Strategy for Nuclear Receptor Modulators.
Topics: Amides; Amidohydrolases; Animals; Blood-Brain Barrier; Brain; Diffusion; Mice; Mice, Inbred C57BL; Molecular Targeted Therapy; Prodrugs; Receptors, Cytoplasmic and Nuclear; Tissue Distribution | 2020 |